148 related articles for article (PubMed ID: 31663261)
1. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Millar BC; Malnarcic CM; McCaughan J; Moore JE
Clin Respir J; 2020 Jan; 14(1):64-68. PubMed ID: 31663261
[No Abstract] [Full Text] [Related]
2. Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study.
Derbali RM; Aoun V; Moussa G; Frei G; Tehrani SF; Del'Orto JC; Hildgen P; Roullin VG; Chain JL
Mol Pharm; 2019 May; 16(5):1906-1916. PubMed ID: 30900903
[TBL] [Abstract][Full Text] [Related]
3. Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis.
Ali H; Orchard C; Mariveles M; Scott S; Alshafi K; Bilton D; Simmonds N
Eur Respir J; 2015 Sep; 46(3):862-5. PubMed ID: 25882803
[No Abstract] [Full Text] [Related]
4. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
McKnight AJ; Shaw A; Goldsmith CE; Clarke L; Millar BC; McCaughan J; Elborn JS; Reid A; Moore JE
Br J Biomed Sci; 2005; 62(1):30-2. PubMed ID: 15816210
[No Abstract] [Full Text] [Related]
5. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
6. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
Millar BC; McCaughan J; Rendall JC; Moore JE
Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).
Lucca F; Guarnieri M; Ros M; Muffato G; Rigoli R; Da Dalt L
Clin Respir J; 2018 Jul; 12(7):2189-2196. PubMed ID: 29498795
[TBL] [Abstract][Full Text] [Related]
8. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
[TBL] [Abstract][Full Text] [Related]
9. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
Richards RM; Hamilton VE; Thomas MR
J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
[TBL] [Abstract][Full Text] [Related]
10. Impact of a Reduction in Susceptibility Testing for
Ponce MC; Svendsen E; Steed L; Flume PA
Am J Respir Crit Care Med; 2020 Jan; 201(1):114-116. PubMed ID: 31469583
[No Abstract] [Full Text] [Related]
11. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
Bosso JA; Mauldin PD; Steed LL
Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility to delafloxacin of Pseudomonas aeruginosa with resistance to other quinolones (ciprofloxacin and levofloxacin).
Jordán-Chaves JDD; Lobato-Cano R; Casas-Ciria J; Freyre-Carillo C; Santotoribio JD; de-la-Rubia-Martin MF
Clin Microbiol Infect; 2024 Mar; 30(3):405-406. PubMed ID: 38103637
[No Abstract] [Full Text] [Related]
13. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
[TBL] [Abstract][Full Text] [Related]
14. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
[TBL] [Abstract][Full Text] [Related]
15. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
16. An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Segatore B; Perilli M; Larosa M; Setacci D; Celenza G; Amicosante G
Int J Antimicrob Agents; 2007 Oct; 30(4):374-6. PubMed ID: 17659863
[No Abstract] [Full Text] [Related]
17. Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Gillespie T; Masterton RG
Int J Antimicrob Agents; 2002 May; 19(5):377-82. PubMed ID: 12007845
[TBL] [Abstract][Full Text] [Related]
18. Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa.
Al-Obaidi H; Kalgudi R; Zariwala MG
Eur J Pharm Biopharm; 2018 Jul; 128():27-35. PubMed ID: 29654885
[TBL] [Abstract][Full Text] [Related]
19. Mutator genes giving rise to decreased antibiotic susceptibility in Pseudomonas aeruginosa.
Wiegand I; Marr AK; Breidenstein EB; Schurek KN; Taylor P; Hancock RE
Antimicrob Agents Chemother; 2008 Oct; 52(10):3810-3. PubMed ID: 18663021
[TBL] [Abstract][Full Text] [Related]
20. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Bozkurt-Güzel C; Gerçeker AA
J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897
[No Abstract] [Full Text] [Related]
[Next] [New Search]
